This is the Header Notice module. It can be used for Cookie Law messages or any other text. Multiple modules with different styles can be added on any page.
Glivec (Gleevec) 400 Mg 30 Film Coated Tablets

Unlimited Blocks

There's no limit to how many blocks you can create. You can position custom product page blocks in different positions and can also display custom blocks on out of stock products only.

FULL PRESCRIBING INFORMATION: CONTENTS*

1     INDICATIONS AND USAGE

1.1     Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML)

1.2     Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy

1.3     Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL)

1.4     Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL)

1.5     Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)

1.6     Aggressive Systemic Mastocytosis (ASM)

1.7     Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL)

1.8     Dermatofibrosarcoma Protuberans (DFSP)

1.9     Kit+ Gastrointestinal Stromal Tumors (GIST)

1.10     Adjuvant Treatment of GIST

2     DOSAGE AND ADMINISTRATION

2.1     Adult Patients with Ph+ CML CP, AP, and BC

2.2     Pediatric Patients with Ph+ CML CP

2.3     Adults Patients with Ph+ ALL

2.4     Pediatric Patients with Ph+ ALL

2.5     MDS/MPD

2.6     ASM

2.7     HES/CEL

2.8     DFSP

2.9     Metastatic or Unresectable GIST

2.10     Adjuvant GIST

2.11     Dose Modification Guidelines

2.12     Dose Adjustment for Hepatotoxicity and Non-Hematologic Adverse Reactions

2.13     Dose Adjustment for Hematologic Adverse Reactions

3     DOSAGE FORMS AND STRENGTHS

4     CONTRAINDICATIONS

5     WARNINGS AND PRECAUTIONS

5.1     Fluid Retention and Edema

5.2     Hematologic Toxicity

5.3     Severe Congestive Heart Failure and Left Ventricular Dysfunction

5.4     Hepatotoxicity

5.5     Hemorrhage

5.6     Gastrointestinal Disorders

5.7     Hypereosinophilic Cardiac Toxicity

5.8     Dermatologic Toxicities

5.9     Hypothyroidism

5.10     Toxicities from Long-Term Use

5.11     Embryo-fetal Toxicity

5.12     Children and Adolescents

5.13     Tumor Lysis Syndrome

5.14     Driving and Using Machinery

6     ADVERSE REACTIONS

6.1     Chronic Myeloid Leukemia

6.2     Hematologic Toxicity 

6.3     Hepatotoxicity

6.4     Adverse Reactions in Pediatric Population

6.5     Adverse Reactions in Other Subpopulations

6.6     Acute Lymphoblastic Leukemia

6.7     Myelodysplastic/Myeloproliferative Diseases

6.8     Aggressive Systemic Mastocytosis

6.9     Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia

6.10     Dermatofibrosarcoma Protuberans

6.11     Gastrointestinal Stromal Tumors

6.12     Additional Data from Multiple Clinical Trials

6.13     Postmarketing Experience

7     DRUG INTERACTIONS

7.1     Agents Inducing CYP3A Metabolism

7.2     Agents Inhibiting CYP3A Metabolism

7.3     Interactions with Drugs Metabolized by CYP3A4

7.4     Interactions with Drugs Metabolized by CYP2D6

7.5     Interaction with Acetaminophen

8     USE IN SPECIFIC POPULATIONS

8.1     Pregnancy

8.3     Nursing Mothers

8.4     Pediatric Use

8.5     Geriatric Use

8.6     Hepatic Impairment

8.7     Renal Impairment

10     OVERDOSAGE

11     DESCRIPTION

12     CLINICAL PHARMACOLOGY

12.1     Mechanism of Action

12.3     Pharmacokinetics

13     NONCLINICAL TOXICOLOGY

13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility

14     CLINICAL STUDIES

14.1     Chronic Myeloid Leukemia

14.2     Pediatric CML

14.3     Acute Lymphoblastic Leukemia

14.4     Pediatric ALL

14.5     Myelodysplastic/Myeloproliferative Diseases

14.6     Aggressive Systemic Mastocytosis

14.7     Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia

14.8     Dermatofibrosarcoma Protuberans

14.9     Gastrointestinal Stromal Tumors

15     REFERENCES

16     HOW SUPPLIED/STORAGE AND HANDLING

17     PATIENT COUNSELING INFORMATION

17.1     Dosing and Administration

17.2     Pregnancy and Breast-Feeding

17.3     Adverse Reactions

17.4     Drug Interactions

17.5     Pediatric

17.6     Driving and Using Machines

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1     INDICATIONS AND USAGE

1.1     Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML)

Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase.

1.2     Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy

Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.

1.3     Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL)

Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia.

1.4     Pediatric patients with Ph+ Acute Lymphoblastic Leukemia (ALL)

Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.

1.5     Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)

Adult patients with myelodysplastic/ myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements.

1.6     Aggressive Systemic Mastocytosis (ASM)

Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation or with c-Kit mutational status unknown.

1.7     Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL)

Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown.

1.8     Dermatofibrosarcoma Protuberans (DFSP)

Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.

1.9     Kit+ Gastrointestinal Stromal Tumors (GIST)

Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors.

1.10     Adjuvant Treatment of GIST

Adjuvant treatment of adult patients following complete gross resection of Kit (CD117) positive GIST.

2     DOSAGE AND ADMINISTRATION

Therapy should be initiated by a physician experienced in the treatment of patients with hematological malignancies or malignant sarcomas, as appropriate. The prescribed dose should be administered orally, with a meal and a large glass of water. Doses of 400 mg or 600 mg should be administered once daily, whereas a dose of 800 mg should be administered as 400 mg twice a day.

In children, Glivec (Gleevec) treatment can be given as a once-daily dose in CML and Ph+ ALL. Alternatively, in children with CML the daily dose may be split into two - one portion dosed in the morning and one portion in the evening. There is no experience with Glivec (Gleevec) treatment in children under 1 year of age.

For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of water or apple juice. The required number of tablets should be placed in the appropriate volume of beverage (approximately 50 mL for a 100 mg tablet, and 200 mL for a 400 mg tablet) and stirred with a spoon. The suspension should be administered immediately after complete disintegration of the tablet(s).

For daily dosing of 800 mg and above, dosing should be accomplished using the 400 mg tablet to reduce exposure to iron.

Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.

2.1     Adult Patients with Ph+ CML CP, AP, and BC

The recommended dose of Glivec (Gleevec) is 400 mg/day for adult patients in chronic phase CML and 600 mg/day for adult patients in accelerated phase or blast crisis.

In CML, a dose increase from 400 mg to 600 mg in adult patients with chronic phase disease, or from 600 mg to 800 mg (given as 400 mg twice daily) in adult patients in accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe non-leukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3 months of treatment, failure to achieve a cytogenetic response after 6-12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response.

2.2     Pediatric Patients with Ph+ CML CP

The recommended dose of Glivec (Gleevec) for children with newly diagnosed Ph+ CML is 340 mg/m2/day (not to exceed 600 mg).

2.3     Adults Patients with Ph+ ALL

The recommended dose of Glivec (Gleevec) is 600 mg/day for adult patients with relapsed/refractory Ph+ ALL.

2.4     Pediatric Patients with Ph+ ALL

The recommended dose of Glivec (Gleevec) to be given in combination with chemotherapy to children with newly diagnosed Ph+ ALL is 340mg/m2/day (not to exceed 600mg).

2.5     MDS/MPD

The recommended dose of Glivec (Gleevec) is 400 mg/day for adult patients with MDS/MPD.

2.6     ASM

The recommended dose of Glivec (Gleevec) is 400 mg/day for adult patients with ASM without the D816V c-Kit mutation. If c-Kit mutational status is not known or unavailable, treatment with Glivec (Gleevec) 400 mg/day may be considered for patients with ASM not responding satisfactorily to other therapies. For patients with ASM associated with eosinophilia, a clonal hematological disease related to the fusion kinase FIP1L1-PDGFRα, a starting dose of 100 mg/day is recommended. Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.

2.7     HES/CEL

The recommended dose of Glivec (Gleevec) is 400 mg/day for adult patients with HES/CEL. For HES/CEL patients with demonstrated FIP1L1-PDGFRα fusion kinase, a starting dose of 100 mg/day is recommended. Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy. 

2.8     DFSP

The recommended dose of Glivec (Gleevec) is 800 mg/day for adult patients with DFSP.

2.9     Metastatic or Unresectable GIST

The recommended dose of Glivec (Gleevec) is 400 mg/day for adult patients with unresectable and/or metastatic, malignant GIST. A dose increase up to 800 mg daily (given as 400 mg twice daily) may be considered, as clinically indicated, in patients showing clear signs or symptoms of disease progression at a lower dose and in the absence of severe adverse drug reactions.

2.10     Adjuvant GIST

The recommended dose of Glivec (Gleevec) is 400 mg/day for the adjuvant treatment of adult patients following complete gross resection of GIST. In clinical trials one year of Glivec (Gleevec) and three years of Glivec (Gleevec) were studied. In the patient population defined in Study 2, three years of Glivec (Gleevec) is recommended [see Clinical Studies (14.8)]. The optimal treatment duration with Glivec (Gleevec) is not known.

2.11     Dose Modification Guidelines

Concomitant Strong CYP3A4 inducers: The use of concomitant strong CYP3A4 inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifampacin, phenobarbital). If patients must be co-administered a strong CYP3A4 inducer, based on pharmacokinetic studies, the dosage of Glivec (Gleevec) should be increased by at least 50%, and clinical response should be carefully monitored [see Drug Interactions (7.1)].

Hepatic Impairment: Patients with mild and moderate hepatic impairment do not require a dose adjustment and should be treated per the recommended dose. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment [see Use in Specific Populations (8.6)].

Renal Impairment: Patients with moderate renal impairment (CrCL=20-39 mL/min) should receive a 50% decrease in the recommended starting dose and future doses can be increased as tolerated. Doses greater than 600 mg are not recommended in patients with mild renal impairment (CrCL=40-59 mL/min). For patients with moderate renal impairment doses greater than 400 mg are not recommended.

Imatinib should be used with caution in patients with severe renal impairment. A dose of 100 mg/day was tolerated in two patients with severe renal impairment [See Warnings and Precautions (5.3), Use in Specific Populations (8.7)].

2.12     Dose Adjustment for Hepatotoxicity and Non-Hematologic Adverse Reactions

If elevations in bilirubin >3 x institutional upper limit of normal (IULN) or in liver transaminases >5 x IULN occur, Glivec (Gleevec) should be withheld until bilirubin levels have returned to a <1.5 x IULN and transaminase levels to <2.5 x IULN. In adults, treatment with Glivec (Gleevec) may then be continued at a reduced daily dose (i.e., 400 mg to 300 mg, 600 mg to 400 mg or 800 mg to 600 mg). In children, daily doses can be reduced under the same circumstances from 340 mg/m2/day to 260 mg/m2/day.

If a severe non-hematologic adverse reaction develops (such as severe hepatotoxicity or severe fluid retention), Glivec (Gleevec) should be withheld until the event has resolved. Thereafter, treatment can be resumed as appropriate depending on the initial severity of the event.

2.13     Dose Adjustment for Hematologic Adverse Reactions

Dose reduction or treatment interruptions for severe neutropenia and thrombocytopenia are recommended as indicated in Table 1.

Table 1 Dose Adjustments for Neutropenia and Thrombocytopenia

ASM associated with eosinophilia
(starting dose 100 mg)

ANC <1.0 x 109/L
and/or
platelets <50 x 109/L

  1. Stop Glivec (Gleevec) until ANC ≥1.5 x 109/L and platelets ≥75 x 109/L
  2. Resume treatment with Glivec (Gleevec) at previous dose (i.e., dose before severe adverse reaction)
     

HES/CEL with FIP1L1-PDGFRα fusion kinase (starting dose 100 mg)

ANC <1.0 x 109/L
and/or
platelets <50 x 109/L

  1. Stop Glivec (Gleevec) until ANC ≥1.5 x 109/L and platelets ≥75 x 109/L
  2. Resume treatment with Glivec (Gleevec) at previous dose (i.e., dose before severe adverse reaction)

Chronic Phase CML (starting dose 400 mg) 

MDS/MPD, ASM and HES/CEL (starting dose 400 mg)

GIST (starting dose
400 mg)

ANC <1.0 x 109/L 
and/or 
platelets <50 x 109/L

  1. Stop Glivec (Gleevec) until ANC ≥1.5 x 109/L and platelets ≥75 x 109/L
  2. Resume treatment with Glivec (Gleevec) at the original starting dose of 400 mg
  3. If recurrence of ANC <1.0 x 109/L and/or platelets <50 x 109/L, repeat step 1 and resume Glivec (Gleevec) at a reduced dose of 300 mg
     
     

Ph+ CML : Accelerated Phase and Blast Crisis (starting dose 600 mg)
Ph+ ALL 
(starting dose 600 mg)

ANC <0.5 x 109/L 
and/or 
platelets <10 x 109/L

  1. Check if cytopenia is related to leukemia (marrow aspirate or biopsy)
  2. If cytopenia is unrelated to leukemia, reduce dose of Glivec (Gleevec) to 400 mg
  3. If cytopenia persists 2 weeks, reduce further to 300 mg
  4. If cytopenia persists 4 weeks and is still unrelated to leukemia, stop Glivec (Gleevec) until ANC ≥1 x 109/L and platelets ≥20 x 109/L and then resume treatment at 300 mg

DFSP
(starting dose 800 mg)

ANC <1.0 x 109/L
and/or
platelets <50 x 109/L

  1. Stop Glivec (Gleevec) until ANC ≥1.5 x 109/L and platelets ≥75 x 109/L
  2. Resume treatment with Glivec (Gleevec) at 600 mg 
  3. In the event of recurrence of ANC <1.0 x 109/L and/or platelets <50 x 109/L, repeat step 1 and resume Glivec (Gleevec) at reduced dose of 400 mg

Pediatric newly diagnosed chronic phase CML 
(starting dose 340 mg/m2)

ANC <1.0 x 109/L
and/or
platelets <50 x 109/L

  1. Stop Glivec (Gleevec) until ANC ≥1.5 x 109/L and platelets ≥75 x 109/L
  2. Resume treatment with Glivec (Gleevec) at previous dose (i.e., dose before severe adverse reaction)
  3. In the event of recurrence of ANC <1.0 x 109/L and/or platelets <50 x 109/L, repeat step 1 and resume Glivec (Gleevec) at reduced dose of 260 mg/m2

3     DOSAGE FORMS AND STRENGTHS

100 mg film coated tablets

Very dark yellow to brownish orange, film-coated tablets, round, biconvex with bevelled edges, debossed with “NVR” on one side, and “SA” with score on the other side

400 mg film coated tablets

Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with “400” on one side with score on the other side, and “SL” on each side of the score

4     CONTRAINDICATIONS

None

5     WARNINGS AND PRECAUTIONS

5.1     Fluid Retention and Edema

Glivec (Gleevec) is often associated with edema and occasionally serious fluid retention [see Adverse Reactions (6.1)]. Patients should be weighed and monitored regularly for signs and symptoms of fluid retention. An unexpected rapid weight gain should be carefully investigated and appropriate treatment provided. The probability of edema was increased with higher Glivec (Gleevec) dose and age >65 years in the CML studies. Severe superficial edema was reported in 1.5% of newly diagnosed CML patients taking Glivec (Gleevec), and in 2%-6% of other adult CML patients taking Glivec (Gleevec). In addition, other severe fluid retention (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) reactions were reported in 1.3% of newly diagnosed CML patients taking Glivec (Gleevec), and in 2%-6% of other adult CML patients taking Glivec (Gleevec). Severe fluid retention was reported in 9% to 13.1% of patients taking Glivec (Gleevec) for GIST [see Adverse Reactions (6.11)].

5.2     Hematologic Toxicity

Treatment with Glivec (Gleevec) is associated with anemia, neutropenia, and thrombocytopenia. Complete blood counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2-3 months). In CML, the occurrence of these cytopenias is dependent on the stage of disease and is more frequent in patients with accelerated phase CML or blast crisis than in patients with chronic phase CML. In pediatric CML patients the most frequent toxicities observed were Grade 3 or 4 cytopenias including neutropenia, thrombocytopenia and anemia. These generally occur within the first several months of therapy [see Dosage and Administration (2.12)].

5.3     Severe Congestive Heart Failure and Left Ventricular Dysfunction

Severe congestive heart failure and left ventricular dysfunction have been reported in patients taking Glivec (Gleevec). Most of the patients with reported cardiac reactions have had other co-morbidities and risk factors, including advanced age and previous medical history of cardiac disease. In an international randomized phase 3 study in 1,106 patients with newly diagnosed Ph+ CML in chronic phase, severe cardiac failure and left ventricular dysfunction were observed in 0.7% of patients taking Glivec (Gleevec) compared to 0.9% of patients taking IFN + Ara-C. Patients with cardiac disease or risk factors for cardiac or history of renal failure should be monitored carefully and any patient with signs or symptoms consistent with cardiac or renal failure should be evaluated and treated.

5.4     Hepatotoxicity

Hepatotoxicity, occasionally severe, may occur with Glivec (Gleevec) [see Adverse Reactions (6.3)]. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of Glivec (Gleevec). Liver function (transaminases, bilirubin, and alkaline phosphatase) should be monitored before initiation of treatment and monthly, or as clinically indicated. Laboratory abnormalities should be managed with Glivec (Gleevec) interruption and/or dose reduction [see Dosage and Administration (2.12)].

When Glivec (Gleevec) is combined with chemotherapy, liver toxicity in the form of transaminase elevation and hyperbilirubinemia has been observed. Additionally, there have been reports of acute liver failure. Monitoring of hepatic function is recommended.

5.5     Hemorrhage

In the newly diagnosed CML trial, 1.8% of patients had Grade 3/4 hemorrhage. In the Phase 3 unresectable or metastatic GIST studies 211 patients (12.9%) reported Grade 3/4 hemorrhage at any site. In the Phase 2 unresectable or metastatic GIST study 7 patients (5%) had a total of 8 CTC Grade 3/4 hemorrhages; gastrointestinal (GI) (3 patients), intra-tumoral (3 patients) or both (1 patient). Gastrointestinal tumor sites may have been the source of GI hemorrhages. Patients should therefore be monitored for gastrointestinal symptoms at the start of therapy. 

5.6     Gastrointestinal Disorders

Glivec (Gleevec) is sometimes associated with GI irritation. Glivec (Gleevec) should be taken with food and a large glass of water to minimize this problem. There have been rare reports, including fatalities, of gastrointestinal perforation.

5.7     Hypereosinophilic Cardiac Toxicity

In patients with hypereosinophilic syndrome with occult infiltration of HES cells within the myocardium, cases of cardiogenic shock/left ventricular dysfunction have been associated with HES cell degranulation upon the initiation of Glivec (Gleevec) therapy. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures and temporarily withholding Glivec (Gleevec). Myelodysplastic/ myeloproliferative disease and systemic mastocytosis may be associated with high eosinophil levels. Performance of an echocardiogram and determination of serum troponin should therefore be considered in patients with HES/CEL, and in patients with MDS/MPD or ASM associated with high eosinophil levels. If either is abnormal, the prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Glivec (Gleevec) should be considered at the initiation of therapy.

5.8     Dermatologic Toxicities

Bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome, have been reported with use of Glivec (Gleevec). In some cases of bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome reported during postmarketing surveillance, a recurrent dermatologic reaction was observed upon re-challenge. Several foreign post-marketing reports have described cases in which patients tolerated the reintroduction of Glivec (Gleevec) therapy after resolution or improvement of the bullous reaction. In these instances, Glivec (Gleevec) was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines.

5.9     Hypothyroidism

Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with Glivec (Gleevec). TSH levels should be closely monitored in such patients.

5.10     Toxicities from Long-Term Use

It is important to consider potential toxicities suggested by animal studies, specifically, liver, kidney, and cardiac toxicity and immunosuppression. Severe liver toxicity was observed in dogs treated for 2 weeks, with elevated liver enzymes, hepatocellular necrosis, bile duct necrosis, and bile duct hyperplasia. Renal toxicity was observed in monkeys treated for 2 weeks, with focal mineralization and dilation of the renal tubules and tubular nephrosis. Increased BUN and creatinine were observed in several of these animals. An increased rate of opportunistic infections was observed with chronic imatinib treatment in laboratory animal studies. In a 39-week monkey study, treatment with imatinib resulted in worsening of normally suppressed malarial infections in these animals. Lymphopenia was observed in animals (as in humans). Additional long-term toxicities were identified in a 2-year rat study. Histopathological examination of the treated rats that died on study revealed cardiomyopathy (both sexes), chronic progressive nephropathy (females) and preputial gland papilloma as principal causes of death or reasons for sacrifice. Non-neoplastic lesions seen in this 2-year study which were not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth. The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals.

5.11     Embryo-fetal Toxicity

Glivec (Gleevec) can cause fetal harm when administered to a pregnant woman. Imatinib mesylate was teratogenic in rats when administered during organogenesis at doses approximately equal to the maximum human dose of 800 mg/day based on body surface area. Significant post-implantation loss was seen in female rats administered imatinib mesylate at doses approximately one-half the maximum human dose of 800 mg/day based on body surface area. Sexually active female patients of reproductive potential taking Glivec (Gleevec) should use highly effective contraception. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in Specific Populations (8.1)].

5.12     Children and Adolescents

Growth retardation has been reported in children and pre-adolescents receiving Glivec (Gleevec). The long term effects of prolonged treatment with Glivec (Gleevec) on growth in children are unknown. Therefore, close monitoring of growth in children under Glivec (Gleevec) treatment is recommended [see Adverse Reactions (6.13)].

5.13     Tumor Lysis Syndrome

Cases of Tumor Lysis Syndrome (TLS), including fatal cases, have been reported in patients with CML, GIST, ALL and eosinophilic leukemia receiving Glivec (Gleevec). The patients at risk of TLS are those with tumors having a high proliferative rate or high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken. Due to possible occurrence of TLS, correction of clinically significant dehydration and treatment of high uric acid levels are recommended prior to initiation of Glivec (Gleevec). 

5.14     Driving and Using Machinery

Reports of motor vehicle accidents have been received in patients receiving Glivec (Gleevec). While most of these reports are not suspected to be caused by Glivec (Gleevec), patients should be advised that they may experience undesirable effects such as dizziness, blurred vision or somnolence during treatment with Glivec (Gleevec). Therefore, caution should be recommended when driving a car or operating machinery.

6     ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates on other clinical trials and may not reflect the rates observed in clinical practice.

6.1     Chronic Myeloid Leukemia

The majority of Glivec (Gleevec)-treated patients experienced adverse reactions at some time. Most reactions were of mild-to-moderate grade, but drug was discontinued for drug-related adverse reactions in 2.4% of newly diagnosed patients, 4% of patients in chronic phase after failure of interferon-alpha therapy, 4% in accelerated phase and 5% in blast crisis.

The most frequently reported drug-related adverse reactions were edema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhea and rash (Table 2 for newly diagnosed CML, Table 3 for other CML patients). Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of Glivec (Gleevec) [see Dosage and Administration (2.12)]. The frequency of severe superficial edema was 1.5%-6%.

A variety of adverse reactions represent local or general fluid retention including pleural effusion, ascites, pulmonary edema and rapid weight gain with or without superficial edema. These reactions appear to be dose related, were more common in the blast crisis and accelerated phase studies (where the dose was 600 mg/

Write a review

Note: HTML is not translated!
    Bad           Good

Glivec (Gleevec) 400 Mg 30 Film Coated Tablets

  • Brand: Novartis
  • Product Code: 8699504091038
  • Availability: In Stock
  • $1thousand_point153.00

Tags: Glivec (Gleevec) 400 Mg 30 Film Coated Tablets, Novartis, All Products, Anticancer